# US 2021/0260126 A1 · Methods for the Storage of Whole Blood, and Compositions Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0260126 A1
- Document ID: US20210260126A1
- Status: Published application
- Kind: A1
- Application number: 17/241,648
- Filed: 2021-04-27
- Published: 2021-08-26
- Earliest claimed: 2015-05-18
- Assignees: Hemanext Inc.
- Applicants: Hemanext Inc.
- Inventors: Tatsuro YOSHIDA
- Web page: https://patentgrep.com/patent/US20210260126A1

## CPC

- A61K 35/18: Erythrocytes (haemoglobin A61K38/42)
- A61K 35/14: Blood; Artificial blood (perfluorocarbons A61K31/02; umbilical cord blood A61K35/51; haemoglobin A61K38/42)
- A61M 1/0281: {Apparatus for treatment of blood or blood constituents prior to transfusion, e.g. washing, filtering or thawing}
- A61M 1/3609: {Physical characteristics of the blood, e.g. haematocrit, urea}
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61M 1/0272: {Apparatus for treatment of blood or blood constituents prior to or for conservation, e.g. freezing, drying or centrifuging}
- A61M 1/36: Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation {; Extra-corporeal blood circuits}
- A61M 2202/0427: Platelets; Thrombocytes
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods and compositions for improved clinical outcomes for trauma patients receiving whole blood transfusion. Methods and compositions for improved clinical outcomes for blood transfusions for cancer patients are also provided.

## Claims

### Claim at position 1

-34. (canceled)

### Claim 35

A leukoreduced whole blood composition for transfusion to a trauma patient in need of multiple transfusions comprising:
oxygen and carbon dioxide reduced leukoreduced whole blood (OCR-LRWB), and
having a pre-storage and storage oxygen saturation (SO2) of 30% or less and a pre-storage and storage partial pressure of carbon dioxide of less than 60 mmHg, and
having a 2,3-DPG level at 15 days that is greater than the initial 2,3-DPG level of said oxygen and carbon dioxide leukoreduced whole blood (OCR-LRWB).

### Claim 36 (depends on 35)

The blood composition of claim 35, wherein the 2,3-DPG level of said OCR-LRWB is at least 80% or higher than the 2,3-DPG level of the blood at day zero.

### Claim 37 (depends on 35)

The blood composition of claim 35, wherein the 2,3-DPG level of said OCR-LRWB is at least 5 to 20 DPG μmol/gHb after 15 days of storage.

### Claim 38

The blood composition of 35, wherein said pre-storage oxygen saturation is less than 20%.

### Claim 39 (depends on 35)

The blood composition of claim 35, wherein said pre-storage partial pressure of carbon dioxide is between 1 and 60 mmHg.

### Claim 40 (depends on 35)

The blood composition of claim 35, wherein said OCR-LRWB comprises an anticoagulant solution selected from citrate-phosphate-dextrose with adenine (CPDA1) or citrate-phosphate-dextrose (CPD).

### Claim 41 (depends on 35)

The blood composition of claim 35, wherein said oxygen and carbon dioxide leukoreduced whole blood (OCR-LRWB) has reduced levels of a biologic response modifier (BRM) selected from the group consisting of a cytokine, a chemokine, an isoprostane, and an oxidized lipid product relative to non-oxygen and carbon dioxide leukoreduced whole blood (non-OCR-LRWB).

### Claim 42 (depends on 41)

The blood composition of claim 41, wherein a patient transfused with said oxygen and carbon dioxide leukoreduced whole blood (OCR-LRWB) has a reduced inflammatory response relative to a patient transfused with non-OCR-LRWB.

### Claim 43 (depends on 41)

The blood composition of claim 41, wherein a patient transfused with said oxygen and carbon dioxide leukoreduced whole blood (OCR-LRWB) has a reduced immune modulation relative to a patient transfused with non-OCR-LRWB.

### Claim 44 (depends on 41)

The blood composition of claim 41, wherein a patient transfused with said oxygen and carbon dioxide leukoreduced whole blood (OCR-LRWB) has a reduced risk of multiple organ dysfunction relative to a patient transfused with non-OCR-LRWB.

### Claim 45 (depends on 41)

The blood composition of claim 41, wherein a patient transfused with said oxygen and carbon dioxide leukoreduced whole blood (OCR-LRWB) has a reduced risk of sepsis relative to a patient transfused with non-OCR-LRWB.

### Claim 46 (depends on 41)

The blood composition of claim 41, wherein a patient transfused with said oxygen and carbon dioxide leukoreduced whole blood (OCR-LRWB) has a reduced risk of infection relative to a patient transfused with non-OCR-LRWB.

### Claim 47 (depends on 41)

The blood composition of claim 41, wherein a patient transfused with said oxygen and carbon dioxide leukoreduced whole blood (OCR-LRWB) has a reduced risk of mortality relative to a patient transfused with non-OCR-LRWB.

### Claim 48 (depends on 41)

The blood composition of claim 41, wherein a patient transfused with said oxygen and carbon dioxide leukoreduced whole blood (OCR-LRWB) has a higher red blood cell (RBC) deformability relative to a patient transfused with non-OCR-LRWB.

### Claim 49 (depends on 41)

The blood composition of claim 41, wherein said blood has equivalent or better coagulation parameters measured by thromboelastography (TEG) when compared to non-OCR-LRWB.

### Claim 50 (depends on 41)

The blood composition of claim 41, wherein said blood has equivalent or better coagulation parameters as determined by PT/PTT, fibrinogen, D-dimer, and thrombin generation assays when compared to non-OCR-LRWB.

### Claim 51 (depends on 41)

The blood composition of any one of claim 41, wherein said blood has equivalent or better platelet function parameters measured by platelet aggregometer when compared to non-OCR-LRWB.

### Claim 52 (depends on 41)

The blood composition of any one of claim 41, wherein said blood has equivalent or better levels of clotting factors including Factor V, Factor VIII, AT, Protein C, or vWF when compared to non-OCR-LRWB.

### Claim 53 (depends on 41)

The blood composition of claim 41, wherein said blood is safe for transfusion into a patient in need thereof for at least three weeks.

### Claim at position 21

-88. (canceled)

### Claim 89 (depends on 35)

The blood composition of claim 35, wherein said pre-storage oxygen saturation is less than 10% or less than 5%.

### Claim 90 (depends on 39)

The blood composition of claim 39, wherein said pre-storage partial pressure of carbon dioxide is between 10 and 60 mmHg, 20 and 40 mmHg, or 1 and 20 mmHg.

### Claim 91 (depends on 35)

The blood composition of claim 35, wherein said patient in need of multiple transfusions is a trauma patient, transplant patient, cardiac surgery patient, obstetrics patient, GI surgery patient, cancer patient, or orthopedic surgery patient.
